Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

1. A compound of formula (Ia):

in which:

R 4 is selected from the group consisting of —SF 5 and —Y 2 —CF 2 —Y 3 ;

R 6 at each occurrence is independently selected from the group consisting of hydrogen, methyl, methoxy, cyano, trifluoromethyl, methoxy-carbonyl, 2-hydroxypropan-2-yl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl;

R 7 at each occurrence is independently selected from the group consisting of hydroxy, methyl, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from the group consisting of cyclopropyl, pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl and 3-azabicyclo[3.1.0]hexan-3-yl; wherein said 3-azabicyclo[3.1.0]hexan-3-yl can be optionally substituted with amino;

Y 1 is selected from the group consisting of N and CR 5 ; wherein R 5 is selected from the group consisting of hydrogen, methoxy and imidazolyl; wherein said imidazolyl is unsubstituted or substituted with methyl;

Y 2 is selected from the group consisting of CF 2 , O and S(O) 0-2 ; and

Y 3 is selected from the group consisting of hydrogen, halo, methyl, difluoromethyl and trifluoromethyl;

Y 4 is selected from the group consisting of CR 6 and N; or the pharmaceutically acceptable salts thereof.

2. The compound of claim 1 of formula (Ib):

in which:

R 4 is selected from the group consisting of —SF 5 and —Y 2 —CF 2 —Y 3 ;

R 6 at each occurrence is independently selected from the group consisting of hydrogen, methyl, methoxy, cyano, trifluoromethyl, methoxy-carbonyl, 2-hydroxypropan-2-yl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl;

R 7 at each occurrence is independently selected from the group consisting of hydroxy, methyl, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from the group consisting of cyclopropyl, pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl and 3-azabicyclo[3.1.0]hexan-3-yl; wherein said 3-azabicyclo[3.1.0]hexan-3-yl can be optionally substituted with amino;

Y 1 is selected from the group consisting of CH and N;

Y 2 is selected from the group consisting of CF 2 , O and S(O) 0-2 ;

Y 3 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

4. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, selected from the group consisting of:

5. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, selected from the group consisting of:

6. The compound of claim 1 of formula (Ic):

in which:

R 4 is selected from the group consisting of —SF 5 and —Y 2 —CF 2 —Y 3 ;

R 6 at each occurrence is independently selected from the group consisting of hydrogen, methyl, methoxy, cyano, trifluoromethyl, methoxy-carbonyl, 2-hydroxypropan-2-yl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl;

R 7 at each occurrence is independently selected from the group consisting of hydroxy, methyl, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from the group consisting of cyclopropyl and 3-azabicyclo[3.1.0]hexan-3-yl;

Y 1 is selected from the group consisting of CH and N;

Y 2 is selected from the group consisting of CF 2 , O and S(O) 0-2 ;

Y 3 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof.

7. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, selected from the group consisting of:

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

9. The compound of claim 1 of formula (Id):

in which:

R 4 is selected from the group consisting of —SF 5 and —Y 2 —CF 2 —Y 3 ;

R 6 at each occurrence is independently selected from the group consisting of hydrogen, methyl, methoxy, methoxy-carbonyl, 2-hydroxypropan-2-yl, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl;

R 7 at each occurrence is independently selected from the group consisting of hydroxy, methyl, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from the group consisting of cyclopropyl and 3-azabicyclo[3.1.0]hexan-3-yl;

Y 1 is selected from the group consisting of CH and N;

Y 2 is selected from the group consisting of CF 2 , O and S(O) 0-2 ;

Y 3 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof.

10. The compound of claim 9 , or the pharmaceutically acceptable salt thereof, selected from the group consisting of:

11. The compound of claim 1 of formula (Ie):

in which:

R 4 is selected from the group consisting of —SF 5 and —Y 2 —CF 2 —Y 3 ;

R 6 at each occurrence is independently selected from the group consisting of hydrogen, methyl, methoxy, cyano, trifluoromethyl, methoxy-carbonyl, 2-hydroxypropan-2-yl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl;

R 7 at each occurrence is independently selected from the group consisting of hydroxy, methyl, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from the group consisting of cyclopropyl and 3-azabicyclo[3.1.0]hexan-3-yl;

Y 1 is selected from the group consisting of CH and N;

Y 2 is selected from the group consisting of CF 2 , O and S(O) 0-2 ;

Y 3 is selected from the group consisting of hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof.

12. The compound of claim 11 , or the pharmaceutically acceptable salts thereof, selected from the group consisting of:

13. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, selected from the group consisting of:

14. A compound, or the pharmaceutically acceptable salt thereof, selected from the group consisting of:

15. A pharmaceutical composition comprising a compound of claim 1 , admixed with at least one pharmaceutically acceptable excipient selected from the group consisting of corn starch, potato starch, tapioca starch, starch paste, pre-gelatinized starch, sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethylcellulose, methyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium aluminum silicate, polyvinyl pyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, agar-agar, sodium carbonate, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, silica, and combinations thereof.

16. The pharmaceutical composition of claim 15 , further comprising an additional therapeutic agent selected from the group consisting of an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent; wherein said anticancer compound is a BCR-ABL1 inhibitor selected from the group consisting of imatinib, nilotinib, dasatinib, bosutinib, ponatinib and bafetinib.

17. A method to treat cancer, comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutical composition of claim 15 ; wherein said cancer is selected from the group consisting of lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system.

18. The method of claim 17 , further comprising administering to the subject an additional therapeutic agent selected from the group consisting of an anticancer drug, a pain medication, an antiemetic, an antidepressant or an anti-inflammatory agent; wherein said anticancer agent is a BCR-ABL1 inhibitor is selected from imatinib, nilotinib, dasatinib, bosutinib, ponatinib and bafetinib.